Q2 2026 revenue rose to SEK 46.8m, driven by XimluciⓇ sales, but gross margin and net results were impacted by one-time adjustments and lower license revenue. Strategic partnerships advanced, and cost-saving measures are expected to improve margins from 2027.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.